Reviewer's report

Title: Why the MDGs need Good Governance in Pharmaceutical Systems to Promote Global Health

Version: 2
Date: 15 December 2013

Reviewer: Joel Lexchin

Reviewer's report:

The authors have successfully addressed my initial concerns but there are still a few other issues that need to be resolved.

Major compulsory revisions

The authors have clarified that they are discussing good governance and corruption in both the public and private sectors and they give examples of the fines levied against companies in the United States but beyond that there is a real absence of any specifics about how the private sector figures into their proposals.

Page 6, second paragraph:
When the authors say that they “go further” what are they going beyond?

Page 7, second paragraph:
Are the examples given here just due to the lack of good governance or are they also due to the poor wages paid to the health care professionals?

Minor essential revisions

There are a number of sentences that I found very awkward to read and these should be rewritten:

Page 5, last sentence on the page.
Page 8, first paragraph, the sentence starting “The public posting…”
Page 11, first paragraph, the sentence starting “This also led…”
Page 12, last paragraph, the sentence starting “It primarily addresses…”

Level of interest: An article of importance in its field

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:

I declare that I have no competing interests.